apceth Biopharma appoints Dusan Kosijer as Chief Financial Officer

apceth Biopharma GmbH (www.apceth.com), a cell therapy company with a proprietary portfolio of genetically modified mesenchymal stem cell therapeutics for the treatment of inflammatory diseases and cancer, and a successful Contract Development and Manufacturing Organisation (CDMO) for cell and gene therapy products, announced today the appointment of Mr Dusan Kosijer as new Chief Financial Officer, effective immediately.

Download Press Release ENG (PDF)